Purpose: Our prospective phase II trial aims to show the feasibility of adjuvant paclitaxel-based concurrent chemoradiotherapy (CCRT) following doxorubicin and cyclophosphamide (AC) to get the survival benefit of taxanes addition and avoid delay of radiotherapy. Patients and Methods: A total of 63 patients with pT1-2, and pN1-3, M0 breast cancer underwent conservative surgery followed by adjuvant 4 cycles AC followed by 4 cycles Paclitaxel 175 mg/m 2 every 3 weeks. Adjuvant radiotherapy started during the first and second cycle of paclitaxel (CCRT). Toxicities evaluated at the base time, weekly during radiation therapy and every 3 months for 24 months for skin, pulmonary, cardiac, lymphedema, subcutaneous fibrosis and cosmoses. Survival reported at 2-year median follow-up. Results: At median follow up time of 24 months (6 - 30), we did not report any toxicity postpone or stop treatment and only two patients had grade III acute dermatitis. Fifty-two patients (82.5%) had satisfactory cosmoses and none of the patients developed local recurrence. Conclusion: Three-weekly paclitaxel during radiotherapy is considered safe without significant complications and acceptable cosmoses with excellent local control and could be considered to avoid radiotherapy delay.
KeywordsBreast CancerBCSConcurrent Radiotherapy and Paclitaxel
Abbas, H., Elyamany, A., Salem, M., Salem, A., Binziad, S. and Gamal, B. (2011) The Optimal Sequence of Radiotherapy and Chemotherapy in Adjuvant Treatment of Breast Cancer. International Archives of Medicine, 4, 35.
Gradishar, W.J., et al. NCCN Guidelines Version 2. 2017 Panel Members Breast Cancer.
Dubey, A., et al. (1999) Concurrent CMF and Radiation Therapy for Early Stage Breast Cancer: Results of a Pilot Study. International Journal of Radiation Oncology * Biology * Physics, 45, 877-884.
Kim, K., et al. (2011) Concurrent versus Sequential Administration of CMF Chemotherapy and Radiotherapy after Breast-Conserving Surgery in Early Breast Cancer. Tumori, 97, 280-285.
Mamounas, E.P., et al. (2005) Paclitaxel after Doxorubicin plus Cyclophosphamide as Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results from NSABP B-28. Journal of Clinical Oncology, 23, 3686-3696.
Liebmann, J., Cook, J.A., Fisher, J., Teague, D. and Mitchell, J.B. (1994) In Vitro Studies of Taxol as a Radiation Sensitizer in Human Tumor Cells. JNCI: Journal of the National Cancer Institute, 86, 441-446.
Weng, W.-W., et al. (2009) [Molecular Mechanism of Radiosensitizing Effect of Paclitaxel]. Ai Zheng, 28, 844-850.
White, J., et al. Breast Cancer Atlas for Radiation Therapy Planning: Consensus Definitions 2 2 Collaborators.
Abbas, H., Mohammad, H. and Aly, M.M.O.M. (2011) Asymmetric Open Field-in-Field Can Replace Wedged Fields in Tangential Whole Breast Irradiation. 10, 250-255.
Cox, J.D., Stetz, J. and Pajak, T.F. (1995) Toxicity Criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology * Biology * Physics, 31, 1341-1346. https://doi.org/10.1016/0360-3016(95)00060-C
RTOG/EORTC Late Radiation Morbidity Scoring Schema。 https://www.rtog.org/ResearchAssociates/AdverseEventReporting/RTOGEORTCLateRadiation MorbidityScoringSchema.aspx
Lind, P.A., Wennberg, B., Gagliardi, G. and Fornander, T. (2001) Pulmonary Complications Following Different Radiotherapy Techniques for Breast Cancer, and the Association to Irradiated Lung Volume and Dose. Breast Cancer Research and Treatment, 68, 199-210. https://doi.org/10.1023/A:1012292019599
Nishioka, A., Ogawa, Y., Hamada, N., Terashima, M., Inomata, T. and Yoshida, S. (1999) Analysis of Radiation Pneumonitis and Radiation-Induced Lung Fibrosis in Breast Cancer Patients after Breast Conservation Treatment. Oncology Reports, 6, 513-517. https://doi.org/10.3892/or.6.3.513
Harris, J.R., Levene, M.B., Svensson, G. and Hellman, S. (1979) Analysis of Cosmetic Results Following Primary Radiation Therapy for Stages I and II Carcinoma of the Breast. International Journal of Radiation Oncology*Biology*Physics, 5, 257-261. https://doi.org/10.1016/0360-3016(79)90729-6
Hébert-Croteau, N., Freeman, C.R., Latreille, J. and Brisson, J. (2002) Delay in Adjuvant Radiation Treatment and Outcomes of Breast Cancer—A Review. Breast Cancer Research and Treatment, 74, 77-94. https://doi.org/10.1023/A:1016089215070
Toledano, A., et al. (2006) Concurrent Administration of Adjuvant Chemotherapy and Radiotherapy after Breast-Conserving Surgery Enhances Late Toxicities: Long-Term Results of the ARCOSEIN Multicenter Randomized Study. International Journal of Radiation Oncology, 65, 324-332. https://doi.org/10.1016/j.ijrobp.2005.12.020
Isaac, N., et al. (2002) Concurrent Cyclophosphamide, Methotrexate, and 5-Fluorouracil Chemotherapy and Radiotherapy for Breast Carcinoma. Cancer, 95, 696-703. https://doi.org/10.1002/cncr.10744
Bellon, J.R., et al. (2004) A Prospective Study of Concurrent Cyclophosphamide/ Methotrexate/5-Fluorouracil and Reduced-Dose Radiotherapy in Patients with Early-Stage Breast Carcinoma. Cancer, 100, 1358-1364. https://doi.org/10.1002/cncr.20136
Taghian, A.G., et al. (2001) Risk of Pneumonitis in Breast Cancer Patients Treated with Radiation Therapy and Combination Chemotherapy with Paclitaxel. Journal of the National Cancer Institute, 93, 1806-1811. https://doi.org/10.1093/jnci/93.23.1806
Burstein, H.J., et al. (2006) Prospective Evaluation of Concurrent Paclitaxel and Radiation Therapy after Adjuvant Doxorubicin and Cyclophosphamide Chemotherapy for Stage II or III Breast Cancer. International Journal of Radiation Oncology, 64, 496-504. https://doi.org/10.1016/j.ijrobp.2005.07.975
Toledano, A., et al. (2007) Phase III Trial of Concurrent or Sequential Adjuvant Chemoradiotherapy after Conservative Surgery for Early-Stage Breast Cancer: Final Results of the ARCOSEIN Trial. Journal of Clinical Oncology, 25, 405-410. https://doi.org/10.1200/JCO.2006.07.8576
Chen, W.C., et al. (2012) A Phase II Study of Radiotherapy and Concurrent Paclitaxel Chemotherapy in Breast-Conserving Treatment for Node-Positive Breast Cancer. International Journal of Radiation Oncology*Biology*Physics, 82, 14-20. https://doi.org/10.1016/j.ijrobp.2010.08.051
Cardoso, M.J., Santos, A.C., Cardoso, J., Barros, H. and Cardoso De Oliveira, M. (2005) Choosing Observers for Evaluation of Aesthetic Results in Breast Cancer Conservative Treatment. International Journal of Radiation Oncology, 61, 879-881. https://doi.org/10.1016/j.ijrobp.2004.06.257
Bielopolski, D., Evron, E., Moreh-Rahav, O., Landes, M., Stemmer, S.M. and Salamon, F. (2017) Paclitaxel-Induced Pneumonitis in Patients with Breast Cancer: Case Series and Review of the Literature. Journal of Chemotherapy, 29, 113-117. https://doi.org/10.1179/1973947815Y.0000000029
Hanna, Y.M., Baglan, K.L., Stromberg, J.S., Vicini, F.A. and Decker, D.A. (2002) Acute and Subacute Toxicity Associated with Concurrent Adjuvant Radiation Therapy and Paclitaxel in Primary Breast Cancer Therapy. The Breast Journal, 8, 149-153. https://doi.org/10.1046/j.1524-4741.2002.08306.x
Abbas, H., Salem, A.A.S., Abou, M., Salem, E. and Binziad, S. (2011) Breast Cancer: Radiotherapy at the South Egypt Cancer Institute. Gastric Breast Cancer, 10, 180-186.